Item 1
(a) Name of Issuer:
Carisma Therapeutics Inc.
(b)
Address of Issuers Principal Executive Offices:
3675 Market Street, Suite 200
Philadelphia, Pennsylvania 19104
Item 2
(a) Names of Persons
Filing:
Each of the following is a reporting person (Reporting Person):
Longview Innovation Corp.
IPG
Cayman LP
CT SPV Investment LP
IPG USA SCO LP
(b) Address or
principal business office or, if none, residence:
The address for the principal business office of the Reporting Persons is:
c/o Longview Innovation Corp.
3411 Silverside Road
Baynard
Building, Suite 252
Wilmington, Delaware 19810
(c) Citizenship:
Reference is made to the response to item 4 on each of pages 2-5 of this Schedule 13G (this
Schedule), which responses are incorporated herein by reference.
(d) Title and Class of Securities:
Common Stock, par value $0.001 per share.
(e) CUSIP No.:
14216R 101
Item 3. If this statement
is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4. Ownership
Reference is hereby made to the responses to items 5-9 and 11 on each of pages 2-5 of this Schedule, which responses are incorporated herein by reference.
Item 5. Ownership of Five Percent
or Less of a Class
Not applicable.